Cardiol Therapeutics (CRDL) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Strategic focus and mission

• Advancing innovative therapies targeting chronic inflammation in heart diseases to modify disease progression and improve quality of life.

• Emphasis on non-immunosuppressive, disease-modifying oral therapeutics for cardiac inflammation.

• Targeting inflammasome activation, a key driver in pericarditis, myocarditis, and heart failure.

• Significant initial market opportunity, with IL-1 blockers generating $500M annually and projected to reach $1B.

• FDA Orphan Designation awarded for the entire pericarditis landscape in the US, covering 160,000 patients.

Clinical development and trial progress

• Lead drug CardiolRx demonstrated rapid, sustained pain reduction and normalization of C-reactive protein in Phase 2 pericarditis trial.

• Phase 3 Maverick program for recurrent pericarditis to enroll 110 patients at 20 centers in the US and Europe, with primary endpoint at 24 weeks.

• Phase 2 Archer program in acute myocarditis enrolled 100 patients across five countries, with top-line data expected in early Q2.

• Subcutaneous (subQ) formulation advancing toward clinical development for heart failure by year-end.

• Near-term catalysts include first patient enrollment in Maverick and Archer data readout in 2024.

Market opportunity and competitive landscape

• US recurrent pericarditis population estimated at 38,000, with many patients nonresponsive to first-line therapies.

• IL-1 blockers, the current third-line therapy, are costly ($280,000/year) and immunosuppressive, with dependency and relapse concerns.

• CardiolRx aims to fill the gap as an oral, non-immunosuppressive, disease-modifying alternative.

• International expansion planned, with orphan drug eligibility pursued in Europe.